This Medudy course is a video tutorial for physicians on the topic “Treatment of Metastatic Cervical Cancer: Tisotumab Vedotin and the KEYNOTE-826 Trial.” The format used here is a “Journal Club Summary,” in which we summarize the latest and most clinically relevant studies for you.
For patients with recurrent or metastatic cervical cancer, treatment options following disease progression on systemic therapy remain limited; therefore, new mechanisms of action and a clear sequencing of the available agents are clinically relevant. This video begins by presenting the mechanism of action of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, as well as its regulatory status. It then discusses the key findings from the KEYNOTE-826 study on the combination of pembrolizumab with platinum-based chemotherapy in first-line therapy.
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by Medudy’s team of doctors.
By the end of this course, you will know:
- the mechanism of action of tisotumab vedotin as an antibody-drug conjugate
- The regulatory status and study data relevant to the approval of tisotumab vedotin
- Key findings from the KEYNOTE-826 study on pembrolizumab as first-line therapy
- The Recommended Sequence of Treatment for Metastatic Cervical Cancer
